Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 157, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2020.103182
Keywords
p53; Cervical cancer; Targeted therapy; Prognosis; Signaling pathway
Categories
Funding
- National Natural Science Foundation of China [31371425]
- Liaoning Provincial Natural Science Foundation of China [20180551061, 20180551174]
Ask authors/readers for more resources
Cervical cancer is a common malignancy affecting women worldwide, with surgical resection being the most effective treatment at early stages. Dysregulation of the tumor suppressor p53 is associated with therapeutic insensitivity and relapse in CC, while restoration of p53 activity can inhibit tumor growth and eliminate drug resistance.
Cervical cancer (CC) is one of most common malignancies affecting women worldwide. To date, surgical resection is the only effective radical remedy for CC at its early stages, while the prognosis of metastatic or recurrent CC is very poor. Dysfunction of the tumor suppressor p53 due to aberrant expression, post-translational modification, mutations, SNPs, and LOH as well as sequestration by viral antigens and MDM2/HDM2-mediated degradation is closely associated with the therapeutic insensitivity and relapse of many malignancies, including CC. Accumulating studies have demonstrated that restoration of p53 activity can induce cell cycle arrest and apoptosis, eliminate radio- and chemotherapy resistance, and inhibit tumor growth in CC cells. Therefore, activation of wild-type p53 as well as restoration of p53 function seems appealing as a therapeutic strategy. In this review, we focus on the potential roles of p53 reactivation in CC treatment and their underlying molecular mechanisms towards the development of novel therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available